Antecedentes Esta la segunda actualización de una revisión publicada anteriormente en la
Biblioteca Cochrane (2015, primera actualización en 2017). La interleucina 5 (IL‐5) es la …

It is estimated that more than 339 million people worldwide suffer from asthma. The leading
cause of asthma development is the breakdown of immune tolerance to inhaled allergens …

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival,
and degranulation of eosinophils. Indeed, during the last years, significant advances have …

Increases in eosinophil numbers are associated with infection and allergic diseases,
including asthma, but there is also evidence that eosinophils contribute to homeostatic …

Background This phase 3 study further characterizes the efficacy and safety of reslizumab (a
humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma …

Background IL-5, a mediator of eosinophil activity, is an important potential treatment target
in patients with uncontrolled asthma. The efficacy of reslizumab, a humanized anti-human IL …

Background Persistent eosinophilic airway inflammation in asthma increases the risk of
exacerbations. In a phase 2b dose-ranging study, we aimed to assess the efficacy and …

Advancing our understanding of mechanisms of immune regulation in allergy, asthma,
autoimmune diseases, tumor development, organ transplantation, and chronic infections …

Eosinophils can regulate local immune and inflammatory responses, and their accumulation
in the blood and tissue is associated with several inflammatory and infectious diseases …

Rationale: Eosinophilic asthma is a phenotype of asthma characterized by the persistence of
eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils …